Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T11164
|
|||||
| Target Name |
Secretory phospholipase A2 (sPLA2)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Varespladib methyl | Drug Info | Phase 3 | Rheumatoid arthritis | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | Varespladib methyl | Drug Info | [1], [3], [4] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43. | |||||
| REF 2 | ClinicalTrials.gov (NCT01130246) VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome. U.S. National Institutes of Health. | |||||
| REF 3 | Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. | |||||
| REF 4 | Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs. 2009 Sep;12(9):585-92. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.